First Allied Advisory Services’s Kite Pharma, Inc. KITE Stock Holding History

First Allied Advisory Services’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-4,498	Closed	-$353K	–	1217
2017 Q1	$353K	Buy	+4,498	New	+$278K	0.02%	720

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

First Allied Advisory Services's KITE Position: Q2 2017 in Review

First Allied Advisory Services sold out of Kite Pharma, Inc. (KITE) in Q2 2017, closing a stake of 4,498 shares — an estimated $353K sold.

First Allied Advisory Services first reported a position in KITE in Q1 2017 and held it in 1 quarter. The position peaked at $353K in Q1 2017. 220 funds tracked by Wall St. Rank hold KITE as of Q2 2017.

First Allied Advisory Services reported no remaining Kite Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
First Allied Advisory Services sold 4,498 Kite Pharma, Inc. shares in Q2 2017, an estimated $353K.
First Allied Advisory Services first reported a position in Kite Pharma, Inc. in Q1 2017 and held it in 1 quarter.
First Allied Advisory Services's Kite Pharma, Inc. position peaked at $353K in Q1 2017.
220 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2017.

Based on First Allied Advisory Services's 13F filing for Q2 2017, filed 14 Aug 2017.